title: Prevalence and causes of long-lasting hepatic dysfunction after heart transplantation: a series of 80 patients.
abstract: The long-term follow-up of 80 heart transplant patients (70 men, 10 women) from January 1982 to July 1985 who had received cyclosporine (CsA) showed a high incidence of mild to severe liver dysfunction. Fifty patients (62.5%) had long-lasting postoperative biological disturbances (alanine amino transferase greater than 2N and/or alkaline phosphatase greater than 1.5N for 3 months or more). Most patients were asymptomatic; eight were icteric, and one had arthralgia. The most common biological feature consisted of isolated elevation of ALAT (27 cases). Assessment of causes led to a definite etiology in 42 patients: 7 cardiac failure, 13 HBsAg-positive liver disease (26%) (chronic persistent hepatitis 8, chronic active hepatitis 2, subacute necrosis 2). Fourteen patients (28%) sustained non-A, non-B (NANB) hepatitis (chronic persistent hepatitis 5, chronic active hepatitis 1, cirrhosis 1), and 7 (14%) sustained a drug-related hepatitis. Liver biopsy and complete virus screening was contributive to the diagnosis in nearly all patients. Additionally, prolonged impairment of liver function tests occurred in 62% of heart transplant recipients, mostly during the first 6 postoperative months. Hepatitis B virus (HBV) and NANB hepatitis accounted for 26% and 28% of the cases of liver dysfunction, respectively; drug-induced hepatitis may have been involved in 14% of the cases. Complete hepatitis virus screening should be performed before heart transplant and in any case of abnormal liver function posttransplantation. HBV vaccination prior to heart transplant is recommended in HBsAg- and HBcAb-negative candidates for heart replacement. Long-term follow-up of these patients is mandatory to assess the severity of these liver dysfunctions.
authors.affiliation: Department of Hepatogastroenterology, Hôpital de la Pitie-Salpetriere, Paris, France.
authors.forename: J F
authors.initials: JF
authors.lastname: Cadranel
authors.forename: P
authors.initials: P
authors.lastname: Grippon
authors.forename: M F
authors.initials: MF
authors.lastname: Mattei
authors.forename: F
authors.initials: F
authors.lastname: Lunel
authors.forename: A
authors.initials: A
authors.lastname: Pauwels
authors.forename: P
authors.initials: P
authors.lastname: Rossant
authors.forename: B
authors.initials: B
authors.lastname: Karkouche
authors.forename: A
authors.initials: A
authors.lastname: Cabrol
authors.forename: G
authors.initials: G
authors.lastname: Chomette
authors.forename: C
authors.initials: C
authors.lastname: Cabrol
mesh_terms: D000293:Adolescent; D000328:Adult; D056486:Chemical and Drug Induced Liver Injury / Q000453:epidemiology / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection; D016027:Heart Transplantation; D006525:Hepatitis, Viral, Human / Q000453:epidemiology / Q000209:etiology* / Q000473:pathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000209:etiology*; D012189:Retrospective Studies